iShares Global Healthcare

WHO confirms Merck's Ervebo vaccine as candidate for Ebola prevention

Multiple Institutional Investors Disclose Increased Stakes in UnitedHealth Group on May 19, 2026

Lilly Asia Ventures Participates in Accro Bioscience's $50 Million Series C Financing

Investment firm Gambit Capital Management makes a new $26.54 million investment in Eli Lilly

Wells Fargo Raises UnitedHealth Group's Price Target to $397

Japan Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea

Eli Lilly Scales Up AI-Driven Drug R&D and Production with Dell Solutions

Merck Plans to Issue $6 Billion in Bonds to Fund Terns Pharmaceutical Acquisition

Judge grants Luigi Mangione's request to suppress evidence in UnitedHealth CEO murder case

UnitedHealth Group will hold its Annual General Meeting on June 2, 2026

Harbour BioMed releases positive preclinical obesity data on its potential rival drug, LET003

Merck Announces Experimental Endometrial Cancer Drug Meets Primary Endpoint in Late-Stage Trial

Novo Nordisk plans to launch Wegovy oral weight-loss drug outside the US, intensifying competition with Eli Lilly

Eli Lilly announces its RET kinase inhibitor selpercatinib has entered a Phase III clinical trial for the first-line treatment of RET fusion-positive lung cancer

Berkshire Hathaway exited its entire position in UnitedHealth Group during the first quarter, causing the stock to slide 4% overnight.

AstraZeneca and Daiichi Sankyo's Enhertu Approved by FDA for HER2+ Early Breast Cancer

AstraZeneca's Baxfendy Approved in US, Outpacing Mineralys Therapeutics

AstraZeneca and Roche Diagnostics APAC Partner to Develop Advanced Pathology Solutions for Breast and Lung Cancer

Eli Lilly and other Fortune 500 pharmaceutical giants establish a presence in Beijing International Pharmaceutical Innovation Park

UnitedHealthcare's D.C. Community Plan Earns NCQA Distinction for Long-Term Services and Supports

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

Pinned News

置顶新闻

ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD

The latest batch of 13F filings has been released: In Q1, Berkshire Hathaway increased its stake in Google Class A shares by over 200%, propelling it to the position of its seventh-largest holding. The firm completely exited positions held for nearly seven years—including Amazon, as well as Visa, Mastercard, and UnitedHealth—while simultaneously making a return to the airline sector after a six-year hiatus, investing $2.65 billion to establish a new position in Delta Air Lines. Bridgewater Associates, meanwhile, initiated new positions in TSMC and the Gold ETF (GLD) for the first time; it also increased its holdings in Amazon (elevating it to its top holding), Nvidia, Broadcom, and Micron. Conversely, the firm liquidated its stakes in Salesforce and ServiceNow, and trimmed its positions in Mastercard, Adobe, and others. Institutional capital is currently converging on AI computing power and safe-haven assets. How many of the stocks in your portfolio have caught the eye of these investment giants?

The latest batch of 13F filings has been released: In Q1, Berkshire Hathaway increased its stake in Google Class A shares by over 200%, propelling it to the position of its seventh-largest holding. The firm completely exited positions held for nearly seven years—including Amazon, as well as Visa, Mastercard, and UnitedHealth—while simultaneously making a return to the airline sector after a six-year hiatus, investing $2.65 billion to establish a new position in Delta Air Lines. Bridgewater Associates, meanwhile, initiated new positions in TSMC and the Gold ETF (GLD) for the first time; it also increased its holdings in Amazon (elevating it to its top holding), Nvidia, Broadcom, and Micron. Conversely, the firm liquidated its stakes in Salesforce and ServiceNow, and trimmed its positions in Mastercard, Adobe, and others. Institutional capital is currently converging on AI computing power and safe-haven assets. How many of the stocks in your portfolio have caught the eye of these investment giants?

Big funds' 13Fs are out: betting on AI compute and safe havens

GILD

ARKG

LABU

SBIO

IBBQ

ProShare Advisors LLC increased its stake in Gilead Sciences, Inc. by 39.1% in Q4, acquiring 623,752 shares, bringing its total to 2,217,290 shares valued at $272.15 million. Other institutional investors also adjusted their holdings. Gilead's stock opened at $129.67, with a market cap of $160.99 billion. The company reported $2.03 EPS, exceeding estimates, and announced a quarterly dividend of $0.82 per share.

Market Beat

Gilead Sciences

Gilead Sciences, Inc.

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

VG Health

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

VanEck Biotech ETF

iShares US Pharma

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

BAYRY

Barclays analyst Charles Pitman maintained a Buy rating on Bayer with a price target of €50.00. Pitman has a 4-star rating with an average return of 11.4%. UBS also rated Bayer as a Buy, while Deutsche Bank issued a Hold rating on the same day.

Tip Ranks

Bayer

Barclays

Bayer Aktiengesellschaft

UBS Group AG

Deutsche Bank AG

Bayer AG

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

Barclays Remains a Buy on Bayer (0P6S)

BAYN

Bayer AG announced that the U.S. FDA has granted Priority Review for Asundexian, an oral Factor Xla inhibitor aimed at preventing secondary strokes. This follows positive results from the Phase 3 OCEANIC-STROKE trial. The Priority Review designation highlights the urgency for new secondary stroke prevention methods. Stroke is a leading cause of death in the U.S., with 795,000 cases annually. Bayer's stock closed at $11.02, up 1.10%.

nasdaq

Nasdaq

Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention

RHHBY

Genentech presented new clinical data for giredestrant, an oral breast cancer drug, ahead of the ASCO 2026 meeting. The Phase III lidERA study will assess benefits across pre- and post-menopausal patients, supporting an FDA submission. Results from the persevERA study, despite missing its main goal, show numerical improvement in endocrine-sensitive disease. Additional analyses from the evERA trial will extend evidence for giredestrant in advanced breast cancer. Early safety and efficacy data for a HER2-targeted therapy will also be presented.

PUBT

Roche

Genentech says Phase III lidERA data support giredestrant in early ER+ breast cancer

NTHI

NeOnc Technologies Holdings, Inc. reported progress in its glioma programs, completing a Phase 1 study of NEO212 and enrolling in a Phase 2a trial of NEO100. The company improved its financial position with a $10 million PIPE financing and reduced its quarterly net loss to $8.8 million. Analysts rate NTHI stock as a Buy with a $20.00 target, though concerns about financial performance persist. NeOnc focuses on CNS cancers, developing drugs under FDA Fast-Track status.

Neonc Tech

NeOnc Advances Glioma Programs and Strengthens Financial Position

HIMS

HIMY

HIMZ

Hims & Hers Health raises $350 million through convertible notes, aimed at supporting global expansion and accelerating AI-driven platform development.

Unusual Whales

Hims & Hers Health

Defiance Leveraged Long +Income HIMS ETF

Defiance Daily Target 2X Long HIMS ETF

iShares US Healthcare Providers

SPDR S&P Health

Hims & Hers Health raises $350 million through convertible notes, aimed at supporting global expansion and accelerating AI-driven platform development.

NBIX

SLNO

Neurocrine Biosciences, Inc. presented new findings on INGREZZA's impact on mild tardive dyskinesia at the APA 2026 meeting, showing significant improvements in patient functional status. The company also completed its acquisition of Soleno Therapeutics for $2.9 billion, enhancing its rare disease portfolio. INGREZZA is FDA-approved for treating tardive dyskinesia and chorea associated with Huntington's disease. Neurocrine's stock closed at $157.21, down 0.76%, but rose 0.50% in after-hours trading.

Neurocrine Biosciences

Soleno Therapeutics

Goldman Sachs

GS Hldg R

Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal

Lupin Limited has received tentative approval from the U.S. FDA for its Revefenacin Inhalation Solution, indicated for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). This product is bioequivalent to Mylan's Yupelri® and has estimated annual sales of USD 260.7 million in the U.S. Lupin is a global pharmaceutical leader based in India, specializing in various therapeutic areas.

prnewswire

Viatris

14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution

LLYX

ELIL

Caliway Biopharmaceuticals presented preclinical data for its fat-reduction candidate CBL-514 combined with GLP-1 drugs at the European Congress on Obesity 2026. The studies showed enhanced weight-loss effects and potential metabolic benefits. The same data will be presented at the American Diabetes Association’s 2026 Scientific Sessions, with plans for human clinical studies this year, aiming for partnerships in obesity treatments.

Eli Lilly

Defiance Daily Target 2X Long LLY ETF

Direxion Daily LLY Bull 2X Shares

Caliway touts preclinical CBL-514 combo data with semaglutide, tirzepatide at ECO 2026

REGN

The FDA has granted breakthrough therapy designation to baxdrostat for uncontrolled hypertension, a significant milestone for patients. Meanwhile, the agency faces instability with leadership departures, raising concerns about regulatory consistency. Additionally, Regeneron has entered a multibillion-dollar collaboration with Parabilis Medicines to develop new therapeutic candidates using AI-driven drug discovery.

Pharmexec

Regeneron Pharma

AstraZeneca

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>

AstraZeneca received FDA approvals for Baxfendy, a hypertension treatment, and Enhertu for early HER2-positive breast cancer. Baxfendy targets uncontrolled hypertension, while Enhertu's approvals cover neoadjuvant and adjuvant settings. These milestones will result in $155 million payments to Daiichi Sankyo. AstraZeneca shares rose 1.56% to $184.42, despite a 9.1% decline over the past month.

Fidelity

AstraZeneca PLC

Mineralys Therapeutics

Daiichi Sankyo Company, Limited

Daiichi Sankyo

S&P 500

AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology Portfolios

The FDA has approved Baxfendy (baxdrostat) for adults with hypertension inadequately controlled on other medications, marking the first aldosterone synthase inhibitor for this condition. The approval is based on the phase 3 BaxHTN trial, showing significant reductions in systolic blood pressure. This innovative treatment targets a root cause of uncontrolled hypertension, potentially transforming clinical practice. AstraZeneca's acquisition of Baxfendy ties it to a broader cardiorenal strategy, with future success dependent on market positioning and long-term outcomes.

<![CDATA[FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry]]>

iShares Global Healthcare(IXJ.US)

ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD

Barclays Remains a Buy on Bayer (0P6S)

Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention

Genentech says Phase III lidERA data support giredestrant in early ER+ breast cancer

NeOnc Advances Glioma Programs and Strengthens Financial Position

Hims & Hers Health raises $350 million through convertible notes, aimed at supporting global expansion and accelerating AI-driven platform development.

Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal

14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution

Caliway touts preclinical CBL-514 combo data with semaglutide, tirzepatide at ECO 2026

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>

AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology Portfolios

<![CDATA[FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry]]>